{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:51:42Z","timestamp":1779292302965,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.06.022","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:44:44Z","timestamp":1625420684000},"page":"e895-e902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System"],"prefix":"10.1016","volume":"21","author":[{"given":"Effrosyni","family":"Apostolidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Lachowiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harinder S","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyebuchi","family":"Ononogbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney Nicole","family":"Miller-Chism","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Udden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Pritchett","family":"Mims","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2021.06.022_bib0001","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.06.022_bib0002","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2021.06.022_bib0003","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2021.06.022_bib0004","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","article-title":"Allogeneic hematopoietic cell transplantation for adult T-cell acute lymphoblastic leukemia","volume":"23","author":"Hamilton","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2021.06.022_bib0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2021.06.022_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2021.06.022_bib0007","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome\u2013positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2021.06.022_bib0008","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2021.06.022_bib0009","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2021.06.022_bib0010","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2021.06.022_bib0011","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2021.06.022_bib0012","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2021.06.022_bib0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2021.06.022_bib0014","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2021.06.022_bib0015","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2021.06.022_bib0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2021.06.022_bib0017","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: effect of race and sex","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2021.06.022_bib0018","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/bmt.2011.214","article-title":"Racial disparities in hematopoietic cell transplantation in the United States","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2021.06.022_bib0019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.leukres.2011.10.018","article-title":"Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience","volume":"36","author":"Bierenbaum","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2021.06.022_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.leukres.2011.10.028","article-title":"It doesn't matter if you're black or white\", does it?","volume":"36","author":"Medeiros","year":"2012","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.clml.2021.06.022_bib0021","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1080\/10428194.2018.1546855","article-title":"Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study","volume":"60","author":"Ritter","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2021.06.022_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174760","article-title":"Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients","volume":"12","author":"Jabo","year":"2017","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.clml.2021.06.022_bib0023","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/cncr.28549","article-title":"Insurance status is related to diffuse large B-cell lymphoma survival","volume":"120","author":"Han","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2021.06.022_bib0024","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbmt.2009.12.529","article-title":"Access to hematopoietic cell transplantation in the United States","volume":"16","author":"Majhail","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.06.022_bib0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bmt.2012.150","article-title":"Race\/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2021.06.022_bib0026","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbmt.2009.08.004","article-title":"The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantation [published correction appears in Biol Blood Marrow Transplant","volume":"16","author":"Murphy","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2021.06.022_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bmt.2012.95","article-title":"Practice variation in physician referral for allogeneic hematopoietic cell transplantation","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2021.06.022_bib0028","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/CLML.2011.n.007","article-title":"Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy","volume":"11","author":"Faderl","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.06.022_bib0029","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2021.06.022_bib0030","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2021.06.022_bib0031","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2021.06.022_bib0032","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2021.06.022_bib0033","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"G\u00f6kbuget","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.06.022_bib0034","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2019-129657","article-title":"Updated results from the Phase II study of hyper-CVAD in sequential combination with blinatumomab in newly diagnosed adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)","volume":"134","author":"Richard-Carpentier","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2021.06.022_bib0035","doi-asserted-by":"crossref","first-page":"E595","DOI":"10.1002\/ajh.24833","article-title":"Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens","volume":"92","author":"Jain","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2021.06.022_bib0036","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2021.06.022_bib0037","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2021.06.022_bib0038","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Perez-Andreu","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.clml.2021.06.022_bib0039","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng.763","article-title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia","volume":"43","author":"Yang","year":"2011","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.clml.2021.06.022_bib0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clml.2021.06.022_bib0041","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.clml.2021.06.022_bib0042","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2021.06.022_bib0043","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.clml.2019.11.003","article-title":"Characteristics and trends of adult acute lymphoblastic leukemia in a large, public safety-net hospital","volume":"20","author":"Gupta","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2021.06.022_bib0044","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.bbmt.2019.06.012","article-title":"Inferior access to allogeneic transplant in disadvantaged populations: a center for international blood and marrow transplant research analysis","volume":"25","author":"Paulson","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.06.022_bib0045","unstructured":"Kaiser Family Foundation (KFF): The cost and coverage implications of the ACA Medicaid expansion: national and State-by-State Analysis, 2012. Available at: https:\/\/www.kff.org\/health-reform\/report\/the-cost-and-coverage-implications-of-the\/."},{"issue":"17","key":"10.1016\/j.clml.2021.06.022_bib0046","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"GIMEMA Investigators. Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2021.06.022_bib0047","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1080\/10428194.2020.1779260","article-title":"Acute lymphoblastic leukemia mortality in Hispanic Americans","volume":"61","author":"Shoag","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2021.06.022_bib0048","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2018-07-862946","article-title":"Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics","volume":"133","author":"Qian","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:40Z","timestamp":1761871180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002512"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}